Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common variations have confounded doctors and left anxious patients without guidance ...

Stanford scientists have identified 380 key genetic variants that significantly influence cancer development, filtering ...

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...